MX388111B - Metodo y composicion para producir agentes regenerativos anti-inflamatorios/anti-catabolicos mejorados a partir de fluido fisiologico autologo. - Google Patents

Metodo y composicion para producir agentes regenerativos anti-inflamatorios/anti-catabolicos mejorados a partir de fluido fisiologico autologo.

Info

Publication number
MX388111B
MX388111B MX2017004131A MX2017004131A MX388111B MX 388111 B MX388111 B MX 388111B MX 2017004131 A MX2017004131 A MX 2017004131A MX 2017004131 A MX2017004131 A MX 2017004131A MX 388111 B MX388111 B MX 388111B
Authority
MX
Mexico
Prior art keywords
chronic
blood
component
mammal
autologous composition
Prior art date
Application number
MX2017004131A
Other languages
English (en)
Other versions
MX2017004131A (es
Inventor
Anthony Galea
Irina Brokhman
Original Assignee
Antnor Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Antnor Ltd filed Critical Antnor Ltd
Publication of MX2017004131A publication Critical patent/MX2017004131A/es
Publication of MX388111B publication Critical patent/MX388111B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14Blood; Artificial blood
    • A61K35/16Blood plasma; Blood serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1841Transforming growth factor [TGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1858Platelet-derived growth factor [PDGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1858Platelet-derived growth factor [PDGF]
    • A61K38/1866Vascular endothelial growth factor [VEGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/20Interleukins [IL]
    • A61K38/2006IL-1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14Extraction; Separation; Purification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14Hydrolases (3)
    • C12N9/48Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)

Abstract

Se describen métodos de producción de una composición autóloga útil para el tratamiento de tejidos conectivos dañados y/o lesionados, tendinosis crónica, desgarres musculares crónicos y/o condiciones degenerativas crónicas de las articulaciones y trastornos inflamatorios de la piel en un mamífero; el método comprende preparar un componente anti-inflamatorio/anti-catabólico de la composición autóloga que comprende IL-1ra y TIMPs; se prepara un componente anti-inflamatorio/anti-catabólico que comprende: colectar sangre del mamífero; suministrar la sangre a un tubo; incubar la sangre a una temperatura de aproximadamente 37°C a aproximadamente 39°C por aproximadamente 24 horas, de preferencia en presencia de citrato de sodio; centrifugar la sangre para separar la sangre en un componente de sobrenadante y una fracción celular; y colectar el componente de sobrenadante; el método comprende además el paso de preparar un componente regenerativo de la composición autóloga que comprende: colectar sangre del mamífero; suministrar la sangre a un tubo en presencia de ácido cítrico a aproximadamente 4%; centrifugar la sangre para separar un componente de plasma rico en plaquetas de la sangre entera; colectar el componente de plasma rico en plaquetas; y mezclar el componente de sobrenadante con el componente de plasma rico en plaquetas para proveer la composición autóloga; se provee también un método de tratamiento de tejidos conectivos dañados y/o lesionados, tendinosis crónica, desgarres musculares crónicos y/o condiciones degenerativas crónicas de las articulaciones y trastornos inflamatorios de la piel en un sujeto con la composición autóloga, y una composición autóloga para el tratamiento de tejidos conectivos dañados y/o lesionados, tendinosis crónica, desgarres musculares crónicos y/o condiciones degenerativas crónicas de las articulaciones y trastornos inflamatorios de la piel en un mamífero, y el uso de la composición autóloga para el tratamiento de tejidos conectivos dañados y/o lesionados, tendinosis crónica, desgarres musculares crónicos y/o condiciones degenerativas crónicas de las articulaciones y trastornos inflamatorios de la piel en un mamífero.
MX2017004131A 2014-09-30 2015-09-30 Metodo y composicion para producir agentes regenerativos anti-inflamatorios/anti-catabolicos mejorados a partir de fluido fisiologico autologo. MX388111B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA2866480A CA2866480A1 (en) 2014-09-30 2014-09-30 Method and composition for producing enhanced anti-inflammatory and regenerative agents from autologous physiological fluid
CA2891445A CA2891445A1 (en) 2014-09-30 2015-05-14 Method and composition for producing enhanced anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid
CA2900537A CA2900537A1 (en) 2014-09-30 2015-08-13 Method and composition for producing enhanced anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid
PCT/CA2015/000521 WO2016049746A1 (en) 2014-09-30 2015-09-30 Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous physiological fluid

Publications (2)

Publication Number Publication Date
MX2017004131A MX2017004131A (es) 2017-06-19
MX388111B true MX388111B (es) 2025-03-19

Family

ID=55590205

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017004131A MX388111B (es) 2014-09-30 2015-09-30 Metodo y composicion para producir agentes regenerativos anti-inflamatorios/anti-catabolicos mejorados a partir de fluido fisiologico autologo.

Country Status (15)

Country Link
US (3) US10532072B2 (es)
EP (1) EP3200817B1 (es)
JP (1) JP6646660B2 (es)
KR (1) KR102455394B1 (es)
CN (1) CN107073083B (es)
AU (1) AU2015327723B2 (es)
CA (4) CA2866480A1 (es)
CL (1) CL2017000670A1 (es)
ES (1) ES2912773T3 (es)
GB (1) GB2546224C (es)
IL (1) IL251082B (es)
LT (1) LT3200817T (es)
MX (1) MX388111B (es)
RU (1) RU2708242C2 (es)
WO (1) WO2016049746A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2866480A1 (en) 2014-09-30 2016-03-30 Antnor Limited Method and composition for producing enhanced anti-inflammatory and regenerative agents from autologous physiological fluid
CA2950659A1 (en) * 2016-12-06 2018-06-06 Antnor Limited Method for the preparation and prolonged storage of growth factors and cytokines obtained from platelet rich plasma
EP3613424A1 (en) * 2018-08-23 2020-02-26 Orthogen AG Novel methods for the production of pharmaceutical agents
WO2020243807A1 (en) * 2019-06-05 2020-12-10 Antnor Limited Method and composition for producing enhanced anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid
RU2747589C1 (ru) * 2019-12-09 2021-05-11 Руслан Яверович Атлуханов Способ лечения повреждения мениска коленного сустава
CA3076046A1 (en) * 2020-03-17 2021-09-17 Antnor Limited Method for producing enhanced anti-inflammatory/anti-catabolic agents from autologous physiological fluid with shortened incubation time
CA3106197A1 (en) * 2021-01-20 2022-07-20 Antnor Limited Method for producing blood plasma product useful in the treatment of viral infections characterized by an uncontrolled release of proinflammatory cytokines
JP7025070B1 (ja) * 2021-05-14 2022-02-24 セルソース株式会社 血液由来成長因子含有組成物及びその調製方法
JP7175055B1 (ja) 2021-05-14 2022-11-18 セルソース株式会社 血液由来成長因子含有組成物及びその調製方法
CN114146096B (zh) * 2021-11-25 2024-04-02 成都清科生物科技有限公司 一种富含细胞因子的条件血清的制备方法及应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0744892B1 (en) 1994-12-16 2003-12-03 Baxter International Inc. Anticoagulant compositions for platelets
DE19903876B4 (de) * 1999-02-01 2006-09-28 Orthogen Gentechnologie Gmbh Verfahren zur in-vitro-Bildung und Anreicherung von Interleukin-1 Rezeptor-Antagonisten
US20030166069A1 (en) 2000-11-28 2003-09-04 Amgen, Inc. Interleukin-1 receptor antagonist-like molecules and uses thereof
US20060177515A1 (en) 2005-02-09 2006-08-10 Reinhold Schmieding Method of producing autogenous or allogenic blood serum and related logistics
GB0700940D0 (en) 2007-01-18 2007-02-28 Univ Newcastle Reverse shoulder prosthesis
PL2259774T3 (pl) 2008-02-27 2013-04-30 Biomet Biologics Llc Sposoby i kompozycje dla wprowadzania antagonisty receptora interleukiny-1
US8460227B2 (en) * 2008-11-17 2013-06-11 Arthrex, Inc. Cytokine concentration system
EP2470162B1 (en) 2009-08-27 2019-03-27 Biomet Biologics, LLC Implantable device for production of interleukin-1 receptor antagonist
KR20140003398A (ko) 2010-09-03 2014-01-09 바이오멧 바이오로직스, 엘엘씨 인터루킨-1 수용체 길항제를 전달하는 방법 및 조성물
KR101313755B1 (ko) * 2010-12-09 2013-10-01 이선민 상피조직 또는 피하조직 재생용 자가혈장의 제조방법 및 이를 함유하는 조성물
US10167310B2 (en) 2012-01-31 2019-01-01 Estar Technologies Ltd System and method for producing interleukin receptor antagonist (IRA)
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
CA2866480A1 (en) 2014-09-30 2016-03-30 Antnor Limited Method and composition for producing enhanced anti-inflammatory and regenerative agents from autologous physiological fluid

Also Published As

Publication number Publication date
CA2962289C (en) 2021-01-19
GB2546224C (en) 2025-04-09
RU2017114523A (ru) 2018-11-07
MX2017004131A (es) 2017-06-19
AU2015327723A1 (en) 2017-04-13
IL251082B (en) 2020-03-31
RU2017114523A3 (es) 2019-05-06
US20240277760A1 (en) 2024-08-22
CA2962289A1 (en) 2016-04-07
RU2708242C2 (ru) 2019-12-05
CA2891445A1 (en) 2016-03-30
CN107073083B (zh) 2021-07-06
CL2017000670A1 (es) 2017-11-10
BR112017006410A2 (pt) 2017-12-19
LT3200817T (lt) 2022-08-10
CN107073083A (zh) 2017-08-18
EP3200817B1 (en) 2022-03-02
US12023352B2 (en) 2024-07-02
EP3200817A4 (en) 2018-06-20
EP3200817A1 (en) 2017-08-09
US20170296583A1 (en) 2017-10-19
IL251082A0 (en) 2017-04-30
WO2016049746A1 (en) 2016-04-07
CA2866480A1 (en) 2016-03-30
JP6646660B2 (ja) 2020-02-14
KR102455394B1 (ko) 2022-10-17
GB2546224B (en) 2020-04-22
GB201706803D0 (en) 2017-06-14
CA2900537A1 (en) 2016-03-30
US20200163991A1 (en) 2020-05-28
GB2546224A (en) 2017-07-12
ES2912773T3 (es) 2022-05-27
US10532072B2 (en) 2020-01-14
AU2015327723B2 (en) 2020-10-22
KR20170063836A (ko) 2017-06-08
JP2017533896A (ja) 2017-11-16

Similar Documents

Publication Publication Date Title
GB2546224A (en) Method and composition for producing enhanced anti-inflammatory/ anti-catabolic and regenerative agents from autologous physiological fluid
SG10201808104RA (en) Cenicriviroc for the treatment of fibrosis
WO2014152029A3 (en) Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors
SV2011003828A (es) Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi)
EA201891374A1 (ru) Замещенные 2-фенил-3-(пиперазинметил)имидазопиридины и их применение
PH12019500440A1 (en) Monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
SG10201809947UA (en) Use of prg4 as an anti-inflammatory agent
CL2017003218A1 (es) Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi)
AU2015287920A8 (en) Micronized Wharton's Jelly
IN2012DN02645A (es)
MY157564A (en) Combination pharmaceutical composition and methods of treating functional diseases or conditions of gastrointestinal tract
WO2018111315A8 (en) PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORγ AND OTHER USES
JP2017533896A5 (es)
WO2014183033A3 (en) G-csf for use in treating or preventing a disease associated with aging in a patient, for administration with a stem-cell containing composition and/or an electromagnetic signal
NZ616048A (en) Administration of iloprost as aerosol bolus
MX2015015036A (es) Metodos para mejorar los perfiles de lipidos utilizando atrasentan.
WO2009140383A3 (en) Aptamers that bind to p-selectin and their use as coagulation, thrombotic, inflammatory, and metastatic disease therapeutics
MX2017001433A (es) Sistema de bioprocesamiento a microescala y metodo para fabricacion de proteina a partir de sangre humana.
PH12014501051A1 (en) Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions
HK1240839A1 (en) Method and composition for producing enhanced anti-inflammatory/anti-catabolic and regenerative agents from autologous physiological fluid
NZ609804A (en) Crystalline forms of an alkoxyimidazol-1-ylmethyl biphenyl carboxylic acid
MX2022011489A (es) Metodo para producir agentes antiinflamatorios/anticatabolicos mejorados a partir de fluido fisiologico autologo.
PH12020551493A1 (en) Triazacyclododecansulfonamide (``tcd``)-based protein secretion inhibitors
MX2016013680A (es) Métodos y composiciones para el tratamiento de trastornos por el almacenamiento de lípidos.